References
- Kawabata Y, Tagawa N, Shirata K, Yoneda M. Participation of the pharmaceutical division in the chemotherapy room for outpatients. Med J Niigata P H 2006;54:30–34.
- Kawabata Y, Nakagawa A, Uchikoshi H, Tamiya Y. The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients. Yakugaku Zasshi 2009;129:359–364.
- Yakult Honsha Corporation. (2005). Oxaliplatin interview form.
- Japan Meteorological Agency Weather Statistics Information. Available at: http://www.jma.go.jp/jma/menu/report.html. Accessed on 15 January 2011.
- Nipro Corporation. (2003). SUREFUSER®A explanatory pamphlet, C1-3000-0311SS.
- Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229–237.
- Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008;26:3523–3529.
- Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326–5334.